Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-02-09

Reporting Person: WILSON KAREN J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	C	18718	$11.57	Acquired	18718	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Convertible Promissory Note	$16.00	C		Disposed		Common Stock ()	Direct

Footnotes

F1: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.

F2: The convertible promissory note ("Convertible Note") had a maturity date of June 1, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.